Adjusted Total Revenue is a non-GAAP financial measure. Adjusted Total Revenue is total revenue excluding Sanofi Supply Sales, Sanofi Royalties and Sanofi Influenza-COVID-19 Combination and Matrix-M ...
The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...
Novavax (NVAX) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 1.51% for the day. Meanwhile, the Dow ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novavax can ...
Novavax on Wednesday said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a stand-alone flu vaccine, sending the company's ...
Novavax (NVAX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to a loss of $0.76 per share a year ago. These figures are ...
Stream Connecticut News for free, 24/7, wherever you are. Novavax could pay up to $475 million to the organization, but the total amount may be less if Gavi decides to order more shots from the ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A U.S. Food and Drug Administration (FDA) logo, a syringe and a vial are seen in this illustration taken May 13, 2025.
GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025. ...